A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday. David Risinger has given his Buy rating due to a combination of factors ...
Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.
Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...
If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as income from Casgevy remains low in the near term, helping to diversify its ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback